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ABSTRACT
Objectives: To explore the perceived acceptability,
advantages and disadvantages of electronic
multicompartment medication devices.
Design: Qualitative study using 8 focus groups and
10 individual semistructured interviews. Recordings
were transcribed and analysed thematically. Strategies
were employed to ensure the findings were credible
and trustworthy.
Participants and setting: Community pharmacists
(n=11), general practitioners (n=9), community nurses
(n=12) and social care managers (n=8) were recruited
from the National Health Service (NHS) and local
authority services. Patients (n=15) who were current
conventional or electronic multicompartment
medication device users or had medication adherence
problems were recruited from community pharmacies.
3 informal carers participated.
Results: Electronic multicompartment medication
devices which prompt the patient to take medication
may be beneficial for selected individuals, particularly
those with cognitive impairment, but who are not
seriously impaired, provided they have a good level of
dexterity. They may also assist individuals where it is
important that medication is taken at fixed time
intervals. These are likely to be people who are being
supported to live alone. No single device suited
everybody; smaller/lighter devices were preferred but
their usefulness was limited by the small number/size
of storage compartments. Removing medications was
often challenging. Transportability was an important
factor for patients and carers. A carer’s alert if
medication is not taken was problematic with multiple
barriers to implementation and no consensus as to
who should receive the alert. There was a lack
of enthusiasm among professionals, particularly
among pharmacists, due to concerns about
responsibility and funding for devices as well as
ensuring devices met regulatory standards for
storage and labelling.
Conclusions: This study provides indicators of which
patients might benefit from an electronic
multicompartment medication device as well as the
kinds of features to consider when matching a patient
with a device. It also highlights other considerations
for successful implementation including issues of
responsibility, regulation and funding.
BACKGROUND
Medication adherence has been identiﬁed as
a global issue; non-adherence can have
serious consequences including hospitalisa-
tion and death.1–7 Non-adherence is multi-
factorial but it is sometimes classiﬁed as
unintentional, for example, practical pro-
blems with the regimen, poor instructions or
poor memory, and at other times intentional
due to a patient’s disagreement with the
need for treatment or to avoid perceived side
effects.2 8 9 It is more likely in people who
take several different medicines such as
those living with multiple morbidities requir-
ing polypharmacy.10
For people who forget to take their medi-
cines, or get confused about them, a variety
of interventions are available to support
them, including multicompartment medica-
tion devices (MMDs). These range from
simple pillboxes and calendar blister packs
to more complex electronic devices. Trials
exploring the effectiveness of preloaded cal-
endar blister packs have yielded heteroge-
neous results.11–14 A Cochrane review of
reminder packaging concluded that this may
improve adherence for patients with selected
conditions but further research is needed.15
However, the review included reminder pack-
aging such as blister packs and reminder
Strengths and limitations of this study
▪ The strength of the study lies in the inclusion of
a wide range of stakeholders who had experience
of either conventional or electronic multicom-
partment medication devices (eMMDs).
▪ This experience, combined with the opportunity
to handle and use the devices ensured the data
were based on actual experiences and contem-
poraneous feedback.
▪ Limitations of the study were the under-
representation of carers, the majority of partici-
pants being professionals and that all patients
were already using a MMD or eMMD.
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charts as well as MMDs and not all of the patient groups
were analogous to older people taking multiple medi-
cines. Recent research and professional guidance has
also highlighted the importance of multidisciplinary
assessment prior to the provision of an MMD, as well as
patient involvement and availability of appropriate
advice and support.16–18
The choice and functionality of electronic MMDs
(eMMDs) is increasing rapidly. Some can prompt when
to take a medication using audible and/or visual signals,
dispense medications at appropriate times, give instruc-
tions to the patient, and contact a caregiver (usually by
mobile internet or text to a carer) if medications are not
removed. The possible beneﬁts, such as more effective
medicines use, improved patient quality of life and
reduced waste, are promoted by manufacturers and
mentioned in government policy.19 However, a recent
review of the literature suggests that while eMMDs have
the potential to improve adherence, the context, usabil-
ity and medical condition inﬂuence their usefulness and
further research is required.20 21 Little is known about
patients’ and professionals’ views of, and experiences
with these devices. The aim of this study (which is part
of a broader programme of work) was to explore the
perceived acceptability, advantages and disadvantages of
eMMDs.
METHODS
Design
A qualitative design was adopted including focus groups
with patients, carers and professional stakeholders, sup-
plemented by individual interviews according to partici-
pant preference. The study was undertaken in one
National Health Service (NHS) Health Board in
Scotland, UK.
Ethics and governance
The study received approval from NHS research ethics
and research management approval from the relevant
NHS Board. Written consent was obtained from all
participants.
Participant selection
Professionals
Invitation packs comprising an introductory letter, infor-
mation sheet and consent form were mailed to a purpos-
ive sample of 25 community pharmacists in the NHS
Board to recruit up to 10 pharmacists from a range of
settings and provision of MMDs. Sampling criteria were:
type of pharmacy (independent contractor/local chain/
national multiple), location (urban/rural), deprivation
(based on the post code of the pharmacy)22 and individ-
ual characteristics of the pharmacist (age/gender).
General practitioners (GPs), community nurses and
social care managers were initially approached through
the local research network and council telecare leads,
respectively, but failed to recruit any participants.
Personal contacts of the research team were then fol-
lowed up and a snowballing technique adopted to reach
the target sample size of 20 GPs/community nurses and
5 social care managers, considered likely to achieve data
saturation.
Patients and carers
Patient inclusion criteria were: aged 16 years or over;
current user of an MMD or eMMD; or people with adher-
ence problems identiﬁed from pharmacy medication
records. Patients who were unable to provide informed
consent or had a score of 24 or below on the Mini Mental
State Examination were excluded.23 Fifteen of the afore-
mentioned 25 community pharmacies from one NHS
Board agreed to mail or hand out study invitation packs
to potentially eligible patients. Those participants who
expressed an interest were visited by the researcher to
seek consent to participate and conﬁrm eligibility. A
maximum variation sample of 15 participants (and their
lay carers if relevant) was sought based on age, gender
and deprivation status of the pharmacy. For eligible parti-
cipants, the researcher administered the Morisky 8-item
Medication Adherence Questionnaire, the Rolyan 9-hole
Peg Board Test to describe participant dexterity and the
Bailey Lovie Reading Test to describe visual acuity
characteristics.24–26 Participants were invited to attend
either a focus group or interview.
Data collection
Focus groups (or individual, semistructured interview
for those unable to attend) were held between
September 2014 and March 2015. A topic guide (see
online supplementary appendix 1) was developed based
on the research questions and reﬁned iteratively as data
collection progressed. Usability testing of a range of
devices was conducted with all participants using a
‘think aloud’ technique. Devices included were those
that could store multiple doses of medication and alert
the patient when medication was due to be taken using
audio or visual alerts and/or had the facility to alert a
carer if medication had not been taken. Devices were
identiﬁed from a systematic review of the literature and
by other relevant local experts20 (see table 1). Opinions
were primarily sought on the presented devices but par-
ticipants also had the opportunity to discuss their own
devices. Focus groups with professionals were mainly
held in university locations or their work place and
those with patients and carers were held at a location
external to the university. Professional interviews were
held in their work place and patients in their own
home. All focus groups and interviews were audio-
recorded and ﬁeld notes were taken. They were con-
ducted by JH, a female researcher with an MSc (includ-
ing training in qualitative research methods),
experience conducting qualitative research and a back-
ground in health services research. At the beginning of
each focus group or interview, the background of the
researcher (no professional expertise or personal
2 Hall J, et al. BMJ Open 2016;6:e012915. doi:10.1136/bmjopen-2016-012915
Open Access
group.bmj.com on October 24, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
experience of the devices) was shared and the reasons
for conducting the research. Only participants and JH
were present during the focus groups and interviews. JH
met patient and carer participants prior to their
participation.
Data management and analysis
All recordings were transcribed and the transcripts
checked against the recording. Transcripts were not
returned to participants for checking. They were ana-
lysed thematically based around a framework of the
research questions. Coding of the transcripts was con-
ducted using NVivo V.10. Constant comparison within
and between cases was used to ensure the analysis repre-
sented all perspectives and negative cases were sought
for each code. Emergent ﬁndings were discussed and
checked with the wider research team (n=5) and the
coding reviewed and reﬁned.
RESULTS
Forty professionals (11 pharmacists, 9 GPs, 12 commu-
nity nurses and 8 social care managers) participated in
six focus groups (n=35) and four interviews (n=5).
Professional characteristics are in tables 2 and 3. Of 340
patients approached, 24 expressed an interest in the
study (7.1%). Fifteen patients were willing and eligible
(15/24, 62.5%), and participated in one of two focus
groups (n=9) or an interview (n=6). One carer partici-
pated in a focus group and two were interviewed. Patient
characteristics are in tables 4 and 5. All patients were
Table 2 Professional participant gender and age
Professional
group
Gender
Female (%):
male (%)
Age
Median years
(range)
Pharmacists 64:36 45 (35–58)*
General
practitioners
67:33 56 (44–62)
Community nurses 83:17 39 (31–56)
Social care
managers
63:37 48 (34–57)†
*Missing for three participants.
†Missing for four participants.
Table 1 eMMD devices used in focus groups
Lifemax Pill Box Reminder Pendant design timer with 2 pill compartments. Alarm sound and
light to remind when medication is due
http://www.lifemaxuk.co.uk/hearing/pendant-pill-box-reminder.html
Lifemax Vibration 5 Alarm Pill Box Medication planner with 5 pill compartments each with a vibration
and/ or sound reminder alarm
http://www.lifemaxuk.co.uk/hearing/5-times-a-day-pill-box-reminder.
html
Medsignals Programmable for up to 4 drugs or doses. Rests on a cradle that
plugs into telephone and electrical lines to allow daily uploading of
dosing history to host server and recharging of battery
http://www.medsignals.com/
Medfolio 28 compartments, sends visual, audio, email and text message
reminders. Includes visual portfolio of all medications. Medication
dosing events communicated to online cloud server
https://www.medfoliopillbox.com/
Pivotell Advance GSM Automatic Pill Dispenser 28 compartments and reminds user by alarm and flashing light.
Only current dose available at any one time. Can be programmed to
send text or email message to carer if medication not taken
http://www.pivotell.co.uk/Pivotell%C2%AE+Advance+GSM
+Automatic+Pill+Dispenser/0_CAAA001/PRAA002.htm
NRS Med-E-Lert Dispenser 28 compartments and reminds user by alarm and flashing light.
Only current dose available at any one time
https://www.nrshealthcare.co.uk/household-aids/
medication-management/medelert-spare-tray-key
E-Box Contains pouches which are filled by robot in the pharmacy,
supports up to 28 days medication. Only current dose available at
any one time. Reminds user by alarm and flashing screen. Dosing
events recorded onto website and can alert carer if medication not
taken
http://robotiktechnology.uk/community-pharmacy/
DoPill (note: despite extensive efforts it was not
possible to obtain the device and it was necessary to
use a picture of the device as a prompt)
28 compartments and reminds user by alarm and flashing light at
each compartment. Can be programmed to alert carer if medication
not taken or wrong medication taken
https://www.telushealth.co/products/pill/
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already using an MMD or eMMD. Focus groups and
interviews were each ∼1 hour in duration. Professional,
patient and carer characteristics are shown in tables 4
and 5.
Three overarching themes were identiﬁed and these
are listed in table 6 along with their subthemes.
Patient-related issues
Patient characteristics
There was consensus between patient and professional
participants that those most likely to beneﬁt from an
eMMD were patients with mild memory loss.
I think people who have maybe got memory difﬁculties,
but otherwise relatively intact, cognitively, would probably
do quite well. The alarm would remind them, they would
understand what was coming out, and how to deal with it.
(GP08)
Some patient participants who were current eMMD
users reported using the device due to difﬁculty remem-
bering to take their tablets.
Well I realised I was forgetting to take my tablets, only
because I felt terrible…So my memory is terrible. So that
[eMMD] reminds me to take my tablets. (P12, current
eMMD user)
Patients using a conventional MMD varied in their
response as to whether an eMMD would beneﬁt them
personally. Some recalled occasions when they had for-
gotten medication and thought a prompt would have
been helpful whereas others reported they did not
usually forget medication. This latter view was echoed by
professionals that MMD users tend to be confused about
their medication regimen (what to take and when to
take it) and are not necessarily forgetful.
We generally bring these systems in, Dosette boxes, when
people are confused about their medication, not neces-
sarily forgetful…So a reminder might be infuriating to
them but it’s not enough…they need instruction…from
a person. (GP07)
Nearly all participants were in agreement that eMMDs
were unlikely to be suitable or acceptable for patients
with more severe memory loss or dementia and profes-
sionals reported negative experiences using eMMDs in
that population.
I think both patients had memory deﬁciency, and just
couldn’t cope with it on their own. One ended up smack-
ing it with a hammer to stop it, to stop it bleeping.
(PH01)
A number of professionals thought people with
mental health problems who tend to have poor medica-
tion adherence could potentially beneﬁt from eMMD
prompts. Similarly, some thought that people with a
learning disability could beneﬁt if appropriately
supported.
I certainly had one mental health patient, where the elec-
tronic device was very good…they used to beat them-
selves up if they’d missed a dose, and take all their
medication as punishment. Whereas, with the electronic
device they couldn’t do that, because it was locked in,
and it obviously prompted them to regularly take the
medication. (PH09)
You could imagine someone with a learning disability
getting quite sort of positively focused on it…So they
could be taught and encouraged to respond to the
alarm. (GP07)
There was broad agreement that people needed to
have a good level of manual dexterity and visual acuity.
However, devices with an audible prompt could be
helpful for patients with sight impairment.
And almost every device requires you to have manual
dexterity, so they have to be fairly physical ﬁt, or have the
dexterity to use them. (GP09)
Table 4 Patient and carer participant gender and age
Gender
Female (%):male (%)
Age
Median years (range)
Patients 73:27 73 (43–92)
Carers 100:0 60 (55–62)
Table 3 Professional participants levels of practice
deprivation
ID Levels of deprivation22
PH01 10
PH02 10
PH03 5
PH04 4
PH05 8
PH06 6
PH07 1
PH08 10
PH09 6
PH10 9
PH11 9
GP01 7
GP02 6
GP03 4
GP04 4
GP05 4
GP06 1
GP07 4
GP08 4
GP09 4
Scores are from 1 (highest levels of deprivation) to 10 (lowest
levels of deprivation).
Note: community nurses and social care managers covered
geographical area containing a multiple levels of deprivation 1–10.
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With this in mind, participants felt the device would
need to be matched to the patient.
It may be that one is perfect, the perfect device for one
patient…another one is perfect for the other. So ease of
use is very subjective to the person who’s using it. (GP06)
It was perceived that elderly people would struggle
with an eMMD although looking forward, increasing
familiarity with technology may impact on usability in
this age group.
It’s not a group of people who are particularly comfort-
able with technology…that in itself, might be something
of a barrier…if you’re thinking about future prooﬁng
some of these things, the people who are starting to get
older now are…more technologically comfortable, than
perhaps people who are very old at the moment. (GP08)
Medication regimen
Accounts among current or previous eMMD users sug-
gested personal alerts could be beneﬁcial for stable
chronic medicines.
…I’ve got antidepressants in there. If I forget to take
them…it’s not a nice time, so it reminds me to take
them and painkillers. If I didn’t take the painkillers, I
would be in a lot worse pain…So the beneﬁts are it
reminds me to take the painkillers so I feel better. (P012,
current eMMD user)
Professionals identiﬁed a number of other timing
issues, for example, avoiding taking all medication at
the same time, once weekly medication and coordinat-
ing the timing of two different medications. Some parti-
cipants felt that a carer’s alert could be beneﬁcial when
it was vital to a patient’s well-being that they took their
medication.
…If you have something, some medication, you’re going
to be ill if you don’t take, or whatever…it’s [personal
reminder] a very good thing to have. (P15, MMD user)
When professionals were handling the devices most
commented that patients likely to be using an eMMD
would be taking multiple medications. However, opinion
differed regarding the number of medications and was
dependent on the physical properties of the devices (see
‘Physical properties’ section). Talking about this issue,
one current eMMD user said:
Table 5 Patient characteristics
Morisky 8-item
Medication Adherence
Questionnaire
MMD or eMMD
user
Bailey Lovie
Reading Test,
British ‘N’ system
Rolyan 9-hole
Peg Test,
dominant hand
Rolyan 9-hole
Peg Test, non-
dominant handID MMD eMMD
P01 0 X 5 30 39
P02 3 X 3 24 26
P03 1 X 5 22 23
P04 0 X 5 21 43
P05 2 X 6 28 32
P06 2 X 8 24 Unable to complete
due to stroke
P07 7 X 5 23 25
P08 3 X 6 20 26
P09 3 X 3 20 26
P10 4 X 4 37 29
P11 3 X 8 27 29
P12 6 X 2.5 23 25
P13 3 X 50 33 34
P14 5 X 6 28 22
P15 3 X 6 26 28
Morisky 8-item Medication Adherence Questionnaire: >2=low adherence; 1 or 2=medium adherence; 0=high adherence.
Bailey Lovie Reading Test, British ‘N’ system: participant is asked to read sequence of words in increasingly smaller print. N ranges from 2
(smallest print) to 80 (largest print). Score indicates smallest print where all words in line accurately read.
Rolyan 9-hole Peg Test: time (in seconds) it takes to individually place the pegs into the board and then remove them.
eMMD, electronic multicompartment medication device; MMD, multicompartment medication device.
Table 6 Thematic coding framework
Overarching themes Subthemes
Patient-related issues Patient characteristics
Medication regimen
Personal and social
circumstances of patients and
their carers
Device-related issues Physical properties
Carer’s alert
Professional-related
issues
Responsibilities
Regulatory issues
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I take about ten tablets a day…So it’s ideal for people
who take about more than ﬁve tablets a day…because
you can’t remember what you’ve taken. (P13, eMMD
user)
Other issues raised were in relation to beginning a
new medication regimen or where it was important they
take the full course.
People quite often forget to take their antibiotics and if
you had a…dose for a couple of weeks that would be
really good. (CN11)
Personal and social circumstances of patients and their
carers
Patient and professional participants thought that
eMMDs would beneﬁt people living alone and sup-
ported to live independently.
That [eMMD] would be fantastic…if you’re in every day
and you’re not going anywhere…Like, when I came
home from hospital, I wasn’t able to move, but I should
have stayed in hospital, but I didn’t. I was like, I want to
get home. (P12)
I think these would be good for people who live alone.
(P11)
Somebody that’s living by themselves that you are sup-
porting to live as normal a life as possible. (PH07)
In contrast, many did not regard an eMMD as an
adjunct to carer visits where other systems appeared to
work in practice and had additional beneﬁts of human
contact.
If they’ve got carers, then we don’t need to be doing
down the route of these…there’s other more, easier
channels to use, like the MAR charts and things. (PH03)
A lot of people who are frail and elderly, living at home,
do beneﬁt from having that little bit of contact with
somebody on a regular basis…I think compliance is
going to be better if you’ve got actually a person talking
to you. (GP07)
Where carers/family were living with a person using
an eMMD, professionals suggested it may facilitate carer
to leave the house for work or socialising.
I imagine somebody looking after an elderly relative,
living with them but going out to work could well say,
now there’re your breakfast tablets; now the machine’s
going to go off at lunchtime, when it goes off take your
tablet. (GP07)
Device-related issues
Physical properties
Participants generally rated smaller and lighter devices
more favourably (Lifemax 2 compartment, Lifemax 5
compartment and Medsignals) particularly for the ability
to take the devices out of the home environment. Larger
and/or heavier devices would not be practical to take out
of the home (E-Box, Medfolio and Pivotell). Devices with
a familiar design (to current MMDs) were also favoured
(DoPill and Medfolio). The compartments and pouches
to store medications were frequently found to be difﬁcult
to open or operate, or anticipated they would be for
other people (DoPill, E-Box pouches, Lifemax 5 com-
partment, Medfolio and Pivotell). In addition, the size of
each compartment was of concern for professionals, who
thought many were too small to accommodate multiple
medications (Lifemax, Medfolio and Pivotell).
If you have reasonable doses of medication…they work…
But if someone is on a higher level of medication…the
carousel jams, because the pills get stuck in it. (SC08)
Some devices had restricted access to the stored medi-
cation, only allowing patient access to the dose due to
be taken (E-Box, NRS Med-E-Lert and Pivotell). This
could be an advantage to avoid taking the wrong dose/
overdose; however, it was also disadvantageous to ﬂexibil-
ity about when and where to take their medication.
I says, so I’ve got to carry that about with me if I go out?
‘Cause all my medication’s in there…tying you to the
house unless you had spare medication about. (P12,
current eMMD user)
Carer’s alert
Participants suggested a carer’s alert may be useful
depending on the medication involved (see ‘Medication
regimen’ section) and reassuring for patients.
I know it’s easier said than done, sort it out and that
would take the pressure off them because they [patients]
would know, hopefully that somebody would come. (P05)
In contrast, an alert to carers could be annoying for
patients who choose to vary timing of medication (false
alerts).
I think it would be very irritating for the patients if…
they’re aware of what they’re doing. So they’ll start to
know which their tablets are and be a bit selective…and
this night they take their sleeping tablet two hours earlier
and stuff like that. (GP01)
Responsibility for monitoring the alert system was of
concern for all participants. All participants questioned
the capacity and practical challenges of paid carers to
take on the responsibility.
So I think it sounds great in practice…but the realities
of…getting a carer back in a reasonable time to deal with
that issue, would be an extremely large workload…on an
already stretched social services. (PH01)
Professionals reported their services could not support
this type of monitoring and thought family and informal
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carers would need to take on the responsibility to
receive alerts. However, participants questioned the cap-
acity and capability of family and informal carers to take
on the additional duty.
If we were giving that out, I think I would only be giving
it out to families who were willing to commit. (CN01)
Professionals suggested that an alert could be used to
establish patterns of adherence that would not require
daily monitoring. These could be collected centrally and
shared with carers and professionals.
Professional-related issues
Responsibilities
There was widespread concern among all participants
as to who would be responsible for ﬁlling the device,
programming the alarm settings, to deal with any pro-
blems that occurred and to pay for them. There was
little consensus regarding who would take on these
responsibilities. Not all patients and carers thought that
pharmacists would be prepared to ﬁll a device and
that they themselves would ﬁnd complex devices
challenging.
I wouldn’t be able to set it up digitally, because I saw him
once opening it up in front of me and it’s all these sec-
tions for your pills. (P10, eMMD user)
Pharmacists said they would not be prepared to ﬁll
and programme the devices due to workload concerns
and this view was echoed by many other professionals.
We had a lot of concerns over them, because who is
responsible for the batteries…Who is going to ﬁll them
up? There was all the issues with the pharmacists in the
past. (SC04)
Many professionals thought that the responsibility for
ﬁlling and programming the devices would have to rest
with the patient’s family. A family member who was a
carer could learn how to use a device but might require
education/training in the ﬁrst instance. However, they
recognised it could be challenging for family members
to do so and reported previous experience where family
members were reluctant to take on this type of
responsibility.
Many professionals were also concerned about who
would be responsible if problems occurred with the
device. Professionals who had experience of using
eMMDs described difﬁculties in resolving problems
when a device was faulty.
From a pharmacy point of view…they’re a bit of a night-
mare to ﬁll and look after. Because you don’t really know
where they’ve been, and until you open it, you don’t
know what the situation is inside it. (PH08)
Participants perceived the devices to be expensive and
raised concern about purchase and implementation
costs. Other costs, including a fee for ﬁlling a device
and training needs for those involved were also high-
lighted as areas of concern.
I don’t imagine that you would get a Council, or a health
board…paying for these to be rolled out anywhere. Most
of these kind of things that are a bit of a help you say to
patients, well this is an option but you have to go and get
it yourself. (GP01)
Regulatory issues
A number of pharmacists raised concerns that many of
the devices do not meet labelling requirements, are not
able to carry all the relevant details about the medica-
tions and medications are not sealed in the devices.
There were also generic concerns about the removal of
medication from original packaging and its effect on
drug stability. Some medications would not be suitable
to include in an eMMD such as unstable medications
like hygroscopics, medication which require to be dis-
solved and drugs whose dosage change frequently like
warfarin. Knowing which drugs were inappropriate to
store together would require training for whoever was
ﬁlling the device.
The problem with these is, they don’t meet pharmacy
requirements, to enable to seal the tablets into the secur-
ity capsule labelling requirements. And be able to access
the relevant information onto the back of the cell.
(PH01)
DISCUSSION
Patients, carers and health/social care professionals
agreed that eMMDs which prompt or remind the
patient to take medication may be beneﬁcial for selected
individuals, particularly those with cognitive impairment,
but who are not seriously impaired, provided they have a
good level of dexterity. eMMDs may also assist indivi-
duals who are being supported to live alone and require
to take medicines at ﬁxed time intervals. Participants
who used eMMDs scored high on dexterity and low on
adherence but were not elderly. No single device suited
everybody; smaller and lighter devices were preferred
but their usefulness was limited by the small number
and size of storage compartments to accommodate mul-
tiple medications. Operating and removing medications
from the devices was often challenging. Transportability
was a consistently important factor for patients and
carers. A carer’s alert if medication is not taken was
problematic with multiple barriers cited to implementa-
tion and no consensus as to who should receive the
alert. There was a particular lack of enthusiasm among
professionals amid concerns about responsibility for
ﬁlling, programming, maintaining and funding devices
as well as ensuring devices met regulatory standards for
storage and labelling of medication.
The strength of this study lies in the inclusion of a
wide range of stakeholders with experience of either
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eMMDs or MMDs. The opportunity to handle and use
the eMMDs ensured the data were based on actual
experiences and contemporaneous feedback on avail-
able eMMDs. The study has a number of limitations.
Carers were under-represented; our method to identify
carers was through the recruited patients but few patient
participants had an informal carer. A further limitation
was that the majority of the participants were profes-
sionals rather than patients and carers. Although typical
for focus group research, a further limitation was the
low response rate among all stakeholder groups, espe-
cially the patients. Despite this, the spread of demo-
graphics for the focus groups likely captured a range of
views on the topic. Patients and carers were from 44 to
over 90 years of age and self-reported medication adher-
ence ranged from low to high. Professionals were drawn
from pharmacies in areas with differing deprivation
levels as well as including a range of ages and balanced
gender mix. Finally, patient participants were already
MMD or eMMD users and the ﬁndings from this study
may not be applicable to patients who have adherence
problems but do not use one of these devices.
We are not aware of any directly comparable studies to
this one. Recent trial data of personal reminders from an
eMMD and text messaging in patients with tuberculosis
reported problems that occurred with the eMMDs.21
These were most commonly incorrect use by the pat-
ient, failure of the device and battery problems and
often necessitated replacement of the device. Despite
these issues, non-adherence was reduced; however, the
population was younger than participants in this study
as well as being from a predominantly rural (farming)
location with low levels of education and ﬁndings
may not be applicable to other populations. In contrast,
McGillicuddy et al27 reported high levels of satisfaction
and usefulness among patients with kidney transplant
with a system of eMMD and text message reminders.
However, this was a small-scale proof of concept study
where the carer’s alert function was received by the study
coordinator, not the clinician. The clinician responsible
for patient care received a weekly report of patient adher-
ence that was tailored to their preferences. Findings from
these studies cannot be translated to the generic poly-
pharmacy population. In addition, they do not address
the issue of transportability of an eMMD that was consist-
ently raised by patients in this study.
This study shows that eMMDs would need to be care-
fully targeted at those community-based individuals most
likely to beneﬁt. The choice of device would depend on
the individual and be matched to their speciﬁc needs.
Consideration of size, weight, capacity, security and
transportability are likely to be important issues for con-
sideration when selecting a device. Personal reminders
to take medications seem to be acceptable but carer’s
alerts may be more problematic. The success of this type
of monitoring will depend on the ongoing agreement of
a person (or organisation) to receive the alert as well as
consistency and clarity in the subsequent response to
the patient. Professionals may be unlikely to support this
function and may depend on families who have both
the capacity and capability to take on this responsibility.
Of greater concern was the general lack of enthusiasm
among professionals and pharmacists in particular. For
eMMDs to be used successfully, detailed planning with
all parties and clear agreement with whoever agrees to
take on responsibilities for ﬁlling, programming, main-
taining and paying for the device and its operation
would have to be agreed. Without such agreements in
place, successful implementation is unlikely. Concerns
about safe storage of medications may also be challen-
ging to overcome with some of the devices used in this
study.
In conclusion, this study provides indicators of which
patients are likely to beneﬁt from an eMMD as well as
the kinds of device features to consider when matching
a patient with an eMMD. It also highlights other consid-
erations for successful implementation including issues
of responsibility and regulation along with a fee struc-
ture to recognise the additional workload for pharma-
cists. These ﬁndings reﬂect the complexity of
non-adherence and caution should be employed in
rolling out the use of eMMDs more widely without
further research. The effectiveness and cost-effectiveness
of eMMDs remains unclear and future research should
focus on robust research methods to address these
matters, taking account of the ﬁndings from this study
to inform the research design.
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